News Wednesday November 2, 2011

Clinical Trials of a Genetically Tailored Therapy for Female Baldness is Expected to Yield Results

PharmaGenoma, Inc., a pharmacogenomics research and development innovator, and its subsidiary HairDX, LLC, has today made known that it has received the approval of the institutional review board (IRB) to commence clinical trials of a genetically tailored therapy for female baldness (Androgenetic Alopecia).

Andy Goren, Chairman and Chief Strategist of PharmaGenoma, Inc and HairDX, LLC, has reiterated that the company's ultimate objective is to transform the field of dermatology through an innovative approach to genetically tailored treatments for familiar skin disorders.

For this purpose, HairDX is set to begin enlisting post menopausal women as patients for this study. Women who meet the requirements for the study will be made to undergo genetic screening. Moreover, if a woman is found to show evidence of a particular genetic variation in her 'Androgen Receptor' gene, she will receive a drug that may have the potential to re-grow her hair. This trial is projected to start in early fall.

As opined by Antonella Tosti, MD, Professor of Dermatology at the University of Bologna in Italy, that, thus far no systemic drug treatment is available for Female Androgenetic Alopecia. The perceived drug trial by HairDX may therefore usher a new era in the treatment of Female Androgenetic Alopecia.

Head of the Crown Human Genome Center at the Department of Molecular Genetics, Weizmann Institute of Science, Professor Doron Lancet, has stated that dermatologists though often prescribe hair loss treatment drugs to women, only a fraction of women respond to those therapies. Should this clinical trial prove successful, dermatologists will be in a position to tailor individual treatments for hair loss based on a woman's genetic makeup.

Since the early part of 2008, HairDX has become the first company to market genetic tests through physicians that predict an individual's risk for male or female pattern androgenetic alopecia.

For the purpose, HairDX uses a CLIA certified laboratory (Clinical Laboratory Improvement Amendments) to perform the genetic analysis. This has helped HairDX offer physicians a powerful screening test for androgenetic alopecia before any visible signs of hair loss are seen. The test results are expected to assist physicians in choosing a course of action that will play a major role in maintaining an individual's hair count.

Bookmark and Share

Latest Stories

Get your daily dose of inspiration from our Best of healthexpress blog , where we showcase some of the most stunning stories and information.

News

Could Obesity treatments serve t...

Scientists have found that through helping obese patients to lose weight, they can also help reduce the number of cases of Obstructive sleep apnea,...

News

Italy called to action for 2 hou...

Italy is a nation that loves it's food. However, ministers have been forced to call it to action, and pose the question as to whether their culture...

News

Toddler's appendix bursts after ...

A 2 year old child, suspected of carrying the H1N1 virus suffered a burst appendix as the result of a mis - diagnosis from health experts. The Tots...

News

Scientists Prove Link between Ob...

22-December-2008 - Recent scientific studies have provided strong evidence to prove a connection between obesity in men and erectile dysfunction....

News

Calorie Overdose can Short Circu...

22-December-2008 - Excessive calorie intake can be a self perpetuating habit which has devastating health effects. This habit sets off a series of...

News

Fake Viagra King And Spam Networ...

A federal Court in Chicago is celebrating an important victory against a global internet spamming group offering, among other things, copied and...

Load More Stories
comments powered by Disqus